{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:09:45Z","timestamp":1765886985445},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,6,1]]},"DOI":"10.1093\/pubmed\/fdm013","type":"journal-article","created":{"date-parts":[[2007,5,10]],"date-time":"2007-05-10T20:44:07Z","timestamp":1178829847000},"page":"199-202","source":"Crossref","is-referenced-by-count":15,"title":["National trends in the use and costs of anti-obesity medications in England 1998\u20132005"],"prefix":"10.1093","volume":"29","author":[{"given":"Janakan","family":"Srishanmuganathan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josip","family":"Car","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azeem","family":"Majeed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2007,5,10]]},"reference":[{"key":"key\n\t\t\t\t20171013172444_FDM013C1","article-title":"Obesity: Preventing and managing the global epidemic","author":"WHO","year":"1998"},{"key":"key\n\t\t\t\t20171013172444_FDM013C2","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1001\/jama.282.16.1523","article-title":"The disease burden associated with obesity","volume":"282","author":"Must","year":"1999","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20171013172444_FDM013C3","unstructured":"Select Committee on Health\n          Health: third report\n          2004\n          (last accessed February 2007)\n          London\n          Stationary Office\n          \n            http:\/\/www.publications.parliament.uk\/pa\/cm200304\/cmselect\/cmhealth\/23\/2302.htm"},{"key":"key\n\t\t\t\t20171013172444_FDM013C4","unstructured":"British Heart Foundation Statistics Webpage\n          (last accessed July 2006)\n          \n            http:\/\/www.heartstats.org"},{"key":"key\n\t\t\t\t20171013172444_FDM013C5","unstructured":"Zaninotto\n              P\n            \n            \n              Wardle\n              H\n            \n            \n              Stamatakis\n              E\n            \n            \n              Mindell\n              J\n            \n            \n              Head\n              J\n            \n          \n          Forecasting obesity to 2010\n          2006\n          (last accessed February 2007)\n          By the Joint Health Service unit on behalf of the Department of Health\n          \n            http:\/\/www.dh.gov.uk\/assetRoot\/04\/13\/86\/29\/04138629.pdf"},{"key":"key\n\t\t\t\t20171013172444_FDM013C6","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/oxfordjournals.bmb.a011615","article-title":"Obesity as a disease","volume":"53","author":"Jung","year":"1997","journal-title":"Br Med Bull"},{"key":"key\n\t\t\t\t20171013172444_FDM013C7","unstructured":"National Institute for Clinical Excellence\n          Obesity\u2014guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children\n          2006\n          (last accessed February 2007)\n          \n            http:\/\/www.nice.org.uk\/guidance\/CG43"},{"key":"key\n\t\t\t\t20171013172444_FDM013C8","article-title":"Datamonitor, Commercial and Pipeline Perspectives: Obesity","year":"2004"},{"key":"key\n\t\t\t\t20171013172444_FDM013C9","unstructured":"The Association of British Pharmaceutical Industry\n          (last accessed July 2006)\n          \n            http:\/\/www.abpi.org.uk"},{"key":"key\n\t\t\t\t20171013172444_FDM013C10","unstructured":"National Institute of Clinical Excellence\n          Orlistat for the treatment of obesity in adults\n          2001\n          (last accessed February 2007)\n          \n            http:\/\/www.nice.org.uk\/guidance\/TA22"},{"key":"key\n\t\t\t\t20171013172444_FDM013C11","doi-asserted-by":"crossref","first-page":"993","DOI":"10.7326\/0003-4819-139-11-200312020-00013","article-title":"Screening and interventions for obesity in adults: summary of the evidence for the US Preventive Services Task Force","volume":"139","author":"McTigue","year":"2003","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20171013172444_FDM013C12","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/bmj.328.7452.1327","article-title":"Fighting obesity: Evidence of effectiveness will be needed to sustain policies","volume":"328","author":"Jain","year":"2004","journal-title":"Br Med J"},{"issue":"21","key":"key\n\t\t\t\t20171013172444_FDM013C13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta8210","article-title":"Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement","volume":"8","author":"Avenell","year":"2004","journal-title":"Health Technol Assess"},{"issue":"2","key":"key\n\t\t\t\t20171013172444_FDM013C14","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1358\/mf.2005.27.2.876281","article-title":"Clinical evidence for drug treatments in obesity-associated hypertensive patients\u2014a discussion paper","volume":"27","author":"Doggrell","year":"2005","journal-title":"Methods Find Exp Clin Pharmacol"},{"issue":"1","key":"key\n\t\t\t\t20171013172444_FDM013C15","first-page":"25","article-title":"The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss","volume":"5","author":"Rowe","year":"2005","journal-title":"Semin Vasc Med"},{"key":"key\n\t\t\t\t20171013172444_FDM013C16","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/archinte.164.9.994","article-title":"The efficacy and safety of sibutramine for weight loss: a systematic review","volume":"164","author":"Arterburn","year":"2004","journal-title":"Arch Intern Med"},{"issue":"163","key":"key\n\t\t\t\t20171013172444_FDM013C17","first-page":"1046","article-title":"National trends in anti-obesity medication use","volume":"12","author":"Stafford","year":"2004","journal-title":"Arch Intern Med"},{"issue":"11","key":"key\n\t\t\t\t20171013172444_FDM013C18","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1038\/oby.2005.234","article-title":"Trends in obesity and overweight-related office visits and drug prescriptions in Canada, 1998 to 2004","volume":"13","author":"Padwal","year":"2005","journal-title":"Obesity Res"},{"key":"key\n\t\t\t\t20171013172444_FDM013C19","unstructured":"Primary care management of adult obesity\n          Dr Foster\n          2005\n          (last accessed December 2006)\n          Available from www.drfoster.co.uk"}],"container-title":["Journal of Public Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jpubhealth\/article-pdf\/29\/2\/199\/4339581\/fdm013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T17:25:02Z","timestamp":1507915502000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jpubhealth\/article\/29\/2\/199\/1506064\/National-trends-in-the-use-and-costs-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5,10]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2007,5,10]]},"published-print":{"date-parts":[[2007,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/pubmed\/fdm013","relation":{},"ISSN":["1741-3850","1741-3842"],"issn-type":[{"value":"1741-3850","type":"electronic"},{"value":"1741-3842","type":"print"}],"subject":[],"published-other":{"date-parts":[[2007,6]]},"published":{"date-parts":[[2007,5,10]]}}}